

Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXIII

**David H. Kessel
Tayyaba Hasan**
Editors

**1–3 February 2014
San Francisco, California, United States**

Sponsored and Published by
SPIE

Volume 8931

Proceedings of SPIE, 1605-7422, V. 8931

SPIE is an international society advancing an interdisciplinary approach to the science and application of light.

Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques
in Photodynamic Therapy XXIII, edited by David H. Kessel, Tayyaba Hasan, Proc. of SPIE
Vol. 8931, 893101 · © 2014 SPIE · CCC code: 1605-7422/14/\$18 · doi: 10.1117/12.2053606

The papers included in this volume were part of the technical conference cited on the cover and title page. Papers were selected and subject to review by the editors and conference program committee. Some conference presentations may not be available for publication. The papers published in these proceedings reflect the work and thoughts of the authors and are published herein as submitted. The publisher is not responsible for the validity of the information or for any outcomes resulting from reliance thereon.

Please use the following format to cite material from this book:

Author(s), "Title of Paper," in *Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXIII*, edited by David H. Kessel, Tayyaba Hasan, Proceedings of SPIE Vol. 8931 (SPIE, Bellingham, WA, 2014) Article CID Number.

ISSN: 1605-7422

ISBN: 9780819498441

Published by

SPIE

P.O. Box 10, Bellingham, Washington 98227-0010 USA

Telephone +1 360 676 3290 (Pacific Time) · Fax +1 360 647 1445

SPIE.org

Copyright © 2014, Society of Photo-Optical Instrumentation Engineers.

Copying of material in this book for internal or personal use, or for the internal or personal use of specific clients, beyond the fair use provisions granted by the U.S. Copyright Law is authorized by SPIE subject to payment of copying fees. The Transactional Reporting Service base fee for this volume is \$18.00 per article (or portion thereof), which should be paid directly to the Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923. Payment may also be made electronically through CCC Online at copyright.com. Other copying for republication, resale, advertising or promotion, or any form of systematic or multiple reproduction of any material in this book is prohibited except with permission in writing from the publisher. The CCC fee code is 1605-7422/14/\$18.00.

Printed in the United States of America.

Publication of record for individual papers is online in the SPIE Digital Library.

SPIE 
Digital Library

SPIDigitalLibrary.org

Paper Numbering: Proceedings of SPIE follow an e-First publication model, with papers published first online and then in print and on CD-ROM. Papers are published as they are submitted and meet publication criteria. A unique, consistent, permanent citation identifier (CID) number is assigned to each article at the time of the first publication. Utilization of CIDs allows articles to be fully citable as soon as they are published online, and connects the same identifier to all online, print, and electronic versions of the publication. SPIE uses a six-digit CID article numbering system in which:

- The first four digits correspond to the SPIE volume number.
- The last two digits indicate publication order within the volume using a Base 36 numbering system employing both numerals and letters. These two-number sets start with 00, 01, 02, 03, 04, 05, 06, 07, 08, 09, 0A, 0B ... 0Z, followed by 10-1Z, 20-2Z, etc.

The CID Number appears on each page of the manuscript. The complete citation is used on the first page, and an abbreviated version on subsequent pages. Numbers in the index correspond to the last two digits of the six-digit CID Number.

Contents

vii	<i>Conference Committee</i>
ix	<i>Introduction</i>

SESSION 1 PHOTODYNAMIC THERAPY I

- 8931 02 **Increased efficacy of photodynamic therapy via sequential targeting (Invited Paper)** [8931-1]
D. Kessel, N. Aggarwal, B. F. Sloane, Wayne State Univ. School of Medicine (United States)
- 8931 06 **Metal-based phthalocyanines as a potential photosensitizing agent in photodynamic therapy for the treatment of melanoma skin cancer** [8931-5]
K. Maduray, B. Odhav, Durban Univ. of Technology (South Africa)

SESSION 2 PHOTODYNAMIC THERAPY II

- 8931 09 **Three-dimensional cell culturing by magnetic levitation for evaluating efficacy/toxicity of photodynamic therapy** [8931-8]
L. G. Sabino, Univ. de São Paulo (Brazil) and Rice Univ. (United States); P. F. C. Menezes, V. S. Bagnato, Univ. de São Paulo (Brazil); G. Souza, Nano3D Biosciences, Inc. (United States); T. C. Killian, Rice Univ. (United States); C. Kurachi, Univ. de São Paulo (Brazil)
- 8931 0B **Evaluation of the Photodynamic Therapy effect using a tumor model in Chorioallantoic Membrane with Melanoma cells** [8931-10]
H. H. Buzzá, L. Pires, V. S. Bagnato Sr., C. Kurachi, Univ. de São Paulo (Brazil)

SESSION 3 PHOTODYNAMIC THERAPY III

- 8931 0C **Development of image-guided targeted two-photon PDT for the treatment of head and neck cancers** [8931-11]
C. W. Spangler, SensoPath Technologies, Inc. (United States); J. R. Starkey, Montana State Univ. (United States); B. Liang, S. Fedorka, SensoPath Technologies, Inc. (United States); H. Yang, H. Jiang, Univ. of Florida (United States)
- 8931 0H **Noninvasive tumor oxygen imaging by photoacoustic lifetime imaging integrated with photodynamic therapy** [8931-16]
Q. Shao, M. A. Biel, S. Ashkenazi, Univ. of Minnesota (United States)

SESSION 4 PHOTODYNAMIC THERAPY IV

- 8931 OK **Recovery of optical properties from interstitial spectroscopy for photodynamic therapy treatment planning** [8931-19]
T. M. Baran, Univ. of Rochester Medical Ctr. (United States); M. C. Fenn, Univ. of Rochester (United States); T. H. Foster, Univ. of Rochester Medical Ctr. (United States) and Univ. of Rochester (United States)

SESSION 5 PHOTODYNAMIC THERAPY V

- 8931 OS **Photodynamic effect of photosensitizer-loaded hollow silica nanoparticles for hepatobiliary malignancies: an in vitro and in vivo study** [8931-28]
X. Deng, L. Xiong, Y. Wen, Z. Liu, D. Pei, Y. Huang, X. Miao, Central South Univ. (China)
- 8931 OT **Photodynamic inactivation of pathogens causing infectious keratitis** [8931-27]
C. Simon, G. Wolf, M. Walther, Technische Univ. Kaiserslautern (Germany); K. Winkler, M. Finke, Univ. des Saarlandes (Germany); D. Hüttenberger, ApoCare Pharma GmbH (Germany); M. Bischoff, B. Seitz, Univ. des Saarlandes (Germany); J. Cullum, H.-J. Foth, Technische Univ. Kaiserslautern (Germany)

SESSION 6 PHOTODYNAMIC THERAPY VI

- 8931 OW **Pulsed light imaging for wide-field dosimetry of photodynamic therapy in the skin** [8931-31]
S. C. Davis, K. Sexton, Thayer School of Engineering at Dartmouth (United States); M. S. Chapman, Dartmouth Hitchcock Medical Ctr. (United States); E. Maytin, The Cleveland Clinic (United States); T. Hasan, Massachusetts General Hospital (United States); B. W. Pogue, Thayer School of Engineering at Dartmouth (United States)
- 8931 OX **Photodynamic therapy of cervical intraepithelial neoplasia** [8931-32]
N. M. Inada, Univ. de São Paulo (Brazil); W. Lombardi, M. F. M. Leite, Univ. Estadual Paulista (Brazil); J. R. Trujillo, Johns Hopkins Univ. (United States); C. Kurachi, V. S. Bagnato, Univ. de São Paulo (Brazil)

SESSION 7 PHOTODYNAMIC THERAPY VII

- 8931 OZ **Porphyrin-based polysilsesquioxane nanoparticles to improve photodynamic therapy for cancer treatment** [8931-34]
J. L. Vivero-Escoto, D. DeCillis, L. Fritts, D. L. Vega, The Univ. of North Carolina at Charlotte (United States)

SESSION 8 PHOTODYNAMIC THERAPY VIII

- 8931 13 **Investigation of dynamic morphological changes of cancer cells during photoimmunotherapy (PIT) by low-coherence quantitative phase microscopy** [8931-38]
M. Ogawa, Hamamatsu Univ. School of Medicine (Japan); T. Yamauchi, H. Iwai, Hamamatsu Photonics K.K. (Japan); Y. Magata, Hamamatsu Univ. School of Medicine (Japan); P. L. Choyke, H. Kobayashi, National Cancer Institute (United States)

8931 14 **ALA-PpIX variability quantitatively imaged in A431 epidermoid tumors using in vivo ultrasound fluorescence tomography and ex vivo assay** [8931-39]
A. V. DSouza, B. P. Flynn, J. R. Gunn, Thayer School of Engineering at Dartmouth (United States); K. S. Samkoe, Geisel School of Medicine at Dartmouth (United States) and Thayer School of Engineering at Dartmouth (United States); S. Anand, E. V. Maytin, Cleveland Clinic Lerner Research Institute (United States); T. Hasan, Massachusetts General Hospital (United States); B. W. Pogue, Thayer School of Engineering at Dartmouth (United States) and Geisel School of Medicine at Dartmouth (United States)

8931 15 **In vitro studies of chlorin e6-assisted photodynamic inactivation of Helicobacter pylori** [8931-40]
C. Simon, Technische Univ. Kaiserslautern (Germany); C. Mohrbacher, Westpfalz-Klinikum GmbH (Germany) and ApoCare Pharma GmbH (Germany); D. Hüttenberger, ApoCare Pharma GmbH (Germany); I. Bauer-Marschall, C. Krickhahn, A. Stachon, Westpfalz-Klinikum GmbH (Germany); H.-J. Foth, Technische Univ. Kaiserslautern (Germany)

Author Index

Conference Committee

Symposium Chairs

James G. Fujimoto, Massachusetts Institute of Technology
(United States)

R. Rox Anderson, Wellman Center for Photomedicine, Massachusetts
General Hospital (United States) and Harvard School of Medicine
(United States)

Program Track Chair

Brian Jet-Fei Wong, Beckman Laser Institute and Medical Clinic
(United States)

Conference Chairs

David H. Kessel, Wayne State University (United States)

Tayyaba Hasan, Massachusetts General Hospital (United States)

Conference Program Committee

Charles J. Gomer, Children's Hospital Los Angeles (United States)

Nancy L. Oleinick, Case Western Reserve University (United States)

Ravindra K. Pandey, Roswell Park Cancer Institute (United States)

Brian W. Pogue, Thayer School of Engineering at Dartmouth
(United States)

Kenneth K. Wang M.D., Mayo Clinic (United States)

Session Chairs

1 Photodynamic Therapy I

David H. Kessel, Wayne State University (United States)

2 Photodynamic Therapy II

Tayyaba Hasan, Massachusetts General Hospital (United States)

3 Photodynamic Therapy III

Imran Rizvi, Massachusetts General Hospital (United States)

Jonathan P. Celli, University of Massachusetts (United States)

4 Photodynamic Therapy IV

Brian W. Pogue, Thayer School of Engineering at Dartmouth
(United States)

- 5 Photodynamic Therapy V
Edward V. Maytin M.D., The Cleveland Clinic (United States)
Merrill A. Biel M.D., University of Minnesota (United States)
- 6 Photodynamic Therapy VI
Kenneth K. Wang M.D., Mayo Clinic (United States)
Keith A. Cengel, University of Pennsylvania School of Medicine
(United States)
- 7 Photodynamic Therapy VII
Conor L. Evans, Wellman Center for Photomedicine (United States)
- 8 Photodynamic Therapy VIII
Charles W. Spangler, Rasiris, Inc. (United States)

Introduction

SPIE has been holding conferences related to photodynamic therapy since 1987, and the topic now appears in conferences other than this one. While reports relating to technology and applications are not ruled out, contributions mainly relate to mechanism of action, pathways to photokilling and similar topics.

In the early days, PDT research was often concerned with identifying the components of the mysterious compound 'HPD', development of new and better light sources, working out exactly what happened when photosensitized tumors were irradiated and identifying clinical indications for PDT. More recently, research is being directed toward 'third generation' problems, e.g., what PDT can tell us about cell biology, and what effects photodamage can have far downstream from the initial interactions. Procedures involving 3D cell cultures and orthotopic tumor implants are bringing experimental techniques closer to accurate predictions for clinical outcomes.

Two concerns are currently limiting the impact PDT is having on health care. Pharmaceutical organizations in the PDT field have not been uniformly successful and have often made significant errors in marketing decisions. Research grants now depend on the perception of 'impact', and this can be affected by this perception. In this environment, it is perhaps remarkable that research into PDT and its applications still persists.

**David H. Kessel
Tayyaba Hasan**

